Abstract
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2–6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer’s disease
Translational Psychiatry Open Access 22 December 2022
-
Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people
Journal of Neuroinflammation Open Access 28 May 2022
-
Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study
Journal of Neuroinflammation Open Access 24 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Blennow, K., de Leon, M.J. & Zetterberg, H. Lancet 368, 387–403 (2006).
Storandt, M., Grant, E.A., Miller, J.P. & Morris, J.C. Neurology 59, 1034–1041 (2002).
Wyss-Coray, T. Nat. Med. 12, 1005–1015 (2006).
Steinman, L. Nat. Immunol. 5, 575–581 (2004).
Huang, R.P. Methods Mol. Biol. 264, 215–231 (2004).
Tusher, V.G., Tibshirani, R. & Chu, G. Proc. Natl. Acad. Sci. USA 98, 5116–5121 (2001).
Tibshirani, R., Hastie, T., Narasimhan, B. & Chu, G. Proc. Natl. Acad. Sci. USA 99, 6567–6572 (2002).
Hansson, O. et al. Lancet Neurol. 5, 228–234 (2006).
Assini, A. et al. Neurology 63, 828–831 (2004).
Simard, A.R., Soulet, D., Gowing, G., Julien, J.P. & Rivest, S. Neuron 49, 489–502 (2006).
Britschgi, M. & Wyss-Coray, T. Int. Rev. Neurobiol. 82, 205–233 (2007).
LeBlanc, A.C. Curr. Alzheimer's Res. 2, 389–402 (2005).
Blalock, E.M. et al. Proc. Natl. Acad. Sci. USA 101, 2173–2178 (2004).
Scherzer, C.R. et al. Proc. Natl. Acad. Sci. USA 104, 955–960 (2007).
Maes, O.C. et al. Neurobiol. Aging, published online 18 September 2006 (doi:10.1016/j.neurobiolaging.2006.08.004).
Acknowledgements
We are grateful to the individuals who participated in this study. We also thank W. Hueber for critical reading and helpful comments on the manuscript, and numerous unnamed staff of our institutions for their efforts in subject recruitment, diagnostic assessment and blood processing. This study was supported by the John Douglas French Alzheimer's Foundation (T.W.-C.), the Alzheimer's Association (T.W.-C.), the US National Institute on Aging (T.W.-C., AG20603; J.A.K., J.F.Q., AG08017; D.R.G., AG05131) and Satoris, Inc. We also acknowledge the support of the Veterans Administration Mental Illness Research, Education and Clinical Center and the various Alzheimer's Centers sponsored by the US National Institute on Aging.
Author information
Authors and Affiliations
Contributions
Experiments were coordinated by S.R., M.B. and T.W.-C. Filter array experiment was done by S.R. with the help of C.H. Cytokine antibody array experiments, cluster analysis and class prediction were done by S.R. with scientific advice from R.T. Computational analysis of functional annotations was done by M.B. and T.W.-C. Blood processing, sample preparation, ELISA, subject data collection and administration was done by M.B. with the help of Y.T.-U. Recruitment of patients and control individuals, disease assessment and blood processing in center-coordinated studies was directed or done by A.B., K.B., L.F.F. D.R.G., M.J., A.K., J.A.K, J.L., B.L.M., L.M., J.F.Q., G.D.R., W.H.R., M.N.S., Y.T.S., D.L.S., M.T., J.T. and J.A.Y. The project was conceived by S.R. and T.W.-C. and scientifically directed by T.W.-C., and the paper written by M.B., T.W.-C. and S.R.
Corresponding author
Ethics declarations
Competing interests
Sandip Ray and Charles Herbert are employees of Satoris, Inc. Robert Tibshirani is a consultant for Satoris, Inc. Tony Wyss-Coray is a co-founder and consultant of Satoris, Inc.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary References, Supplementary Figs. 1–4, Supplementary Tables 1–3 (PDF 1350 kb)
Supplementary Data
Data sets (XLS 589 kb)
Rights and permissions
About this article
Cite this article
Ray, S., Britschgi, M., Herbert, C. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359–1362 (2007). https://doi.org/10.1038/nm1653
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1653
This article is cited by
-
Advances in the development of new biomarkers for Alzheimer’s disease
Translational Neurodegeneration (2022)
-
Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people
Journal of Neuroinflammation (2022)
-
Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study
Journal of Neuroinflammation (2022)
-
Application of QPLEXTM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition
Experimental & Molecular Medicine (2022)
-
The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer’s disease
Translational Psychiatry (2022)